Sarizotan
Sarizotan is a drug that was initially developed for the treatment of Parkinson's disease and schizophrenia. It is a selective 5-HT1A receptor and D2 receptor partial agonist. Sarizotan was developed by Merck KGaA, a German multinational pharmaceutical, chemical and life sciences company.
History
Sarizotan was first synthesized in the late 1990s as a potential treatment for neurological disorders. Early clinical trials showed promise in treating symptoms of Parkinson's disease and schizophrenia. However, further development was halted due to a lack of efficacy in larger clinical trials.
Mechanism of Action
Sarizotan acts as a partial agonist at the 5-HT1A and D2 receptors. The 5-HT1A receptor is a subtype of the 5-HT receptor that binds the neurotransmitter serotonin, and is thought to be responsible for the regulation of mood and anxiety. The D2 receptor is a G protein-coupled receptor that binds the neurotransmitter dopamine, and is involved in numerous neurological processes including motivation, pleasure, and reward.
Clinical Trials
In the early 2000s, Sarizotan underwent clinical trials for the treatment of Parkinson's disease and schizophrenia. The drug showed promise in early trials, but failed to show significant efficacy in larger, phase III trials. As a result, Merck KGaA discontinued the development of Sarizotan for these indications.
In 2015, the drug was repurposed for the treatment of Rett syndrome, a rare genetic postnatal neurological disorder. The drug is currently in phase III clinical trials for this indication.
Potential Uses
While Sarizotan has not been approved for any indications, it is currently being studied for potential use in treating Rett syndrome. The drug has shown promise in early trials, and if successful, could provide a much-needed treatment option for this rare disorder.
See Also
Sarizotan
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
